A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects.
To assess safety of SB-656933 following repeat dosing for 14 days.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||See Detailed Description|
- Assess safety of SB-656933 after repeat doses. [ Time Frame: after repeat doses ]
- Investigate concentrations of SB-656933 in the body and how long it remains in the body over 14 days of repeat dosing. [ Time Frame: 14 days of repeat dosing. ]
|Study Start Date:||June 2007|
|Study Completion Date:||September 2007|
|Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
A randomised, double-blind, placebo controlled, dose ascending, parallel group study to evaluate the safety, tolerability, steady state pharmacokinetics and pharmacodynamics of SB-656933-AAA following repeated doses in healthy adult subjects. The pharmacokinetic interaction between repeated doses of SB-656933-AAA and single dose of simvastatin will also be assessed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00504439
|GSK Investigational Site|
|London, United Kingdom, NW10 7NS|
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|